GlassScriptPhysician profile
Avi A Ostrowsky
NPI 1699953513
$1,410.73
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $311.07 | 2019 | |
| Amgen INC. | $154.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.63 | 2019 | |
| Amarin Pharma, INC. | $133.75 | 2019 | |
| Abbvie INC. | $130.17 | 2019 | |
| Corcept Therapeutics | $126.67 | 2019 | |
| Antares Pharma, INC. | $117.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $116.81 | 2019 | |
| Tandem Diabetes Care, INC. | $113.88 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.12 | 2019 | |
| Novo Nordisk INC | $14.59 | 2019 | |
| Shire North American Group INC | $14.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avi Ostrowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.